J
John-Kenyon American Eye Institute | New Albany, IN
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
-Ranibizumab
KPI-121
Bevacizumab
Ranibizumab
AGN-195263
Lifitegrast
Triamcinolone Acetonide
Difluprednate
Ranibizumab+Deferred
Pemafibrate
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
1 of 18 total trials
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...
Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2
Trial sponsors
K
S
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems